T-wave alternans often are a precursor to ventricular fibrillation and thus sudden cardiac death. It has been suggested that spatially discordant alternans (SDA) of action potential duration may lead to T-wave alternans, but the underlying mechanisms of SDA development are not clear. Previous studies have proposed preexisting action potential duration heterogeneities and steep dependence of conduction velocity in the myocardium on the preceding diastolic interval as possible causes of SDA. Our experiments demonstrate that a new mechanism associated with pacing history, ie, short-term memory, might also underlie SDA formation in the heart. In addition, we show that the heterogeneity of action potential duration does not necessarily correlate with the onset of alternans. Our findings have significant clinical relevance because they suggest that new dynamic factors such as the rate at which the heart muscle is paced also may play a role in the development of SDA and subsequently ventricular fibrillation. This suggests that cardiac memory needs to be considered an additional factor that can contribute to arrhythmia initiation. Ultimately, our findings can be used to define a new paradigm in the clinic for testing arrhythmia inducibility and need to be considered in the design of antiarrhythmic drugs. See p 17.
Gender and Outcome in Adult Congenital Heart Disease
Gender differences in prognosis have frequently been reported in cardiovascular disease but less so in adult congenital heart disease. In the CONgenital CORvitia (CONCOR) national registry of adults with congenital heart disease (nϭ7414), we found that women had a 33% higher risk of pulmonary hypertension, a 33% lower risk of aortic outcomes, a 47% lower risk of endocarditis, and a 55% lower risk of an implantable cardioverter-defibrillator implant. These findings should stimulate basic and clinical research to advance the knowledge on gender-specific issues in adult congenital heart disease. See p 26.
Association of Insulin Resistance and Inflammation With Peripheral Arterial Disease: The National Health and Nutrition Examination Survey, 1999 to 2004
Peripheral arterial disease (PAD) is an important manifestation of systemic atherosclerosis. Systemic inflammation and insulin resistance are closely linked pathological states, and each contributes to the development of atherosclerosis. However, the specific association of insulin resistance with PAD and the influence of insulin resistance on the relationship between inflammation and PAD have not been established. Using data from the National Health and Nutrition Examination Survey 1999 to 2004, we found that insulin resistance, as measured by the homeostasis model of insulin resistance, is strongly associated with PAD independently of known cardiovascular risk factors. Furthermore, we found that the presence of insulin resistance blunts the association between inflammation, as measured by C-reactive protein, and PAD. These findings suggest a direct link between PAD and insulin resistance along its entire spectrum and highlight the complex interplay of insulin resistance and inflammation in atherosclerosis. See p 33.
Effect of Doxazosin Gastrointestinal Therapeutic System as Third-Line Antihypertensive Therapy on Blood Pressure and Lipids in the Anglo-Scandinavian Cardiac Outcomes Trial
The use of doxazosin in the management of hypertension has declined after publication of the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT) because of concerns about its safety, particularly with regard to heart failure. In view of this, investigators from the Anglo-Scandinavian Cardiac Outcomes Study-Blood Pressure Lowering Arm (ASCOT-BPLA) conducted an observational analysis of the blood pressurelowering efficacy and safety of modified-release doxazosin used as a common third-line agent in study participants whose blood pressure was uncontrolled despite their other randomized study drugs (either amlodipine and perindopril or atenolol and bendroflumethiazide). Among 10 069 participants who received doxazosin for a median of 12 months of uninterrupted treatment, blood pressure fell by an average of almost 12/7 mm Hg. This was associated with modest reductions in total and LDL cholesterol but a small rise in fasting plasma glucose concentrations. Doxazosin was generally well tolerated; 7.5% of recipients discontinued the drug because of adverse events, most commonly dizziness, fatigue, headache, and edema. There was no apparent excess of heart failure (a rigorously defined and validated secondary end point in ASCOT) among those who received doxazosin, despite the fact that they had more severe hypertensive disease (higher systolic blood pressure and more left ventricular hypertrophy at baseline) than those who did not receive the drug. The authors acknowledge the limitations of the uncontrolled, observational data while concluding that they provide evidence to support the efficacy and safety of modified-release doxazosin used as third-line therapy in the treatment of hypertension. See p 42. Abciximab reduces major adverse cardiac events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Intracoronary abciximab bolus application results in high local drug concentrations and consequently might be more effective than a standard intravenous bolus. In the present randomized, controlled trial, intracoronary abciximab bolus application with subsequent 12-hour continuous intravenous infusion showed reduced no reflow and infarct size as assessed by contrastenhanced magnetic resonance imaging. Furthermore, myocardial perfusion measured by early ST-segment resolution was significantly better in patients treated by intracoronary abciximab application, and there was a trend toward improved angiographic perfusion. On the other hand, there was no increased risk from this direct application. If the infarct size and no-reflow reduction and the improvement in perfusion can be translated into an improved clinical outcome, a larger trial powered to detect differences in outcome will be warranted. See p 49.
Intracoronary Compared With Intravenous Bolus
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Results of a Double-Blind, Placebo-Controlled Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients With Critical Limb Ischemia
Critical limb ischemia continues to be associated with a high incidence of limb loss and mortality. Patients frequently have multiple associated comorbidities that place them at high risk for open surgical bypass. Endovascular approaches are often not an option because of the extent of disease, and they have limited durability. There is no effective medical therapy for critical limb ischemia. Therapeutic angiogenesis through gene or stem cell delivery to the ischemic limb is a developing technology that attempts to improve perfusion to the ischemic limb. Concerns exist about the potential for gene therapy-mediated therapeutic angiogenesis to promote tumor growth or the progression of proliferative diabetic retinopathy. The present study demonstrates that hepatocyte growth factor plasmid gene therapy is safe and well tolerated. In addition, there is a potential indication of efficacy. Given the results of this phase I/II study, future studies are warranted to determine the efficacy of this agent on the more clinically relevant end points of wound healing, major amputation, and patient survival. See p 58.
Mechanical Inhibition of Angiogenesis at the Saphenofemoral Junction in the Surgical Treatment of Varicose Veins: Early Results of a Blinded Randomized Controlled Trial
The major frustration in the treatment of varicose veins is recurrence. After surgery, this occurs in 40% to 60% after 5 to 10 years and even earlier after sclerotherapy. Although there are a number of contributing factors, neovascularization with regeneration of venous channels is most common, as shown by ultrasound imaging and measurement of reflux. Prevention of neovascular venous reconnection by placing a mechanical obstacle to this process at the site of surgery has been suggested. This study tested this in a sizable surgical randomized controlled trial with 398 limbs, in which the active treatment group had a patch of polytetrafluoroethylene placed over the site of ligation of the saphenofemoral junction. Follow-up after 3 years showed the ultrasound-detectable recurrence at the saphenofemoral junction to be consistently reduced by 50% whether the surgery was for severe venous disease or for previous recurrence. However, not all neovascular reconnection was prevented. Ultrasound imaging in these instances demonstrated the newly formed vessels to skirt around the patch. Histological examination of the excised polytetrafluoroethylene patch, as shown in this study, confirmed the ability of neovascular vessels to track around the patch and reconnect to the superficial venous system. Whether these more circuitous neovascularizations will become clinically significant is not clear yet, but the potential clinical benefit of the reduced neovascularization is evident from the lower Venous Clinical Severity Score in the patch group after 3 years. However, the more reliable establishment of the clinical utility of the patch will require the 5-year assessment to be completed. See p 66.
Impact of Plasma Oxidized Low-Density Lipoprotein Removal on Atherosclerosis
A consensus has been reached that lowering plasma low-density lipoprotein (LDL) inhibits atherosclerosis progression. However, whether lowering plasma oxidized LDL (oxLDL) alone contributes to preventing atherosclerosis remains uncertain. The antiatherogenic effects of antioxidant therapy that may inhibit oxLDL formation are controversial because most clinical trials yielded negative results. Here, it has been shown that removal of oxLDL from the circulation has a very strong effect against atherosclerosis. In this study, lectin-like oxLDL receptor 1 (LOX-1), an oxLDL receptor, was expressed ectopically in the livers of apolipoprotein E-deficient mice (LOX-1 mice), using adenoviral gene transfer, to remove oxLDL from the circulation. Intriguingly, a transient decrease in plasma oxLDL, without affecting non-oxLDL cholesterol levels, completely inhibited atherosclerotic progression. Systemic oxidative stress was shown to be decreased in LOX-1 mice. Thus, oxLDL plays very important roles in atherosclerosis formation, and the underlying mechanisms may involve both direct (foam cell formation) and indirect (increased oxidative stress) effects. In addition, smooth muscle cells in the surface areas of atherosclerotic plaques were increased in LOX-1 mice, suggesting that oxLDL makes plaques vulnerable, possibly leading to plaque ruptures. Thus, the results of this study provide potential therapeutic targets for atherosclerosis, ie, treatments that would potently lower plasma oxLDL, including inhibition of oxLDL formation and removal of oxLDL from the circulation. These promising strategies may contribute to the prevention of not only atherosclerosis formation but also the development of acute coronary syndrome. See p 75.
